5 affordable SPF serums for your skincare routine if you're over face creams

If you're tired of thick, heavy sun creams or want to avoid pesky white cast, a skincare expert has recommended using an SPF serum instead - so we found 5 affordable ones to try
There's an easier way apply sun cream to your face - and it's not in a face cream. The newest sun block on the block comes in serum form and it's everywhere. With so many brands offering different types of SPF face creams, SPF serums are taking over - but what's the difference?
If you'd rather avoid a thick SPF face cream, an SPF serum offers a great alternative, and could incorporate into your makeup routine a lot easier too, thanks to its lightweight texture.
According to consultant dermatologist, Dr Derrick Phillips, there are a number benefits of using a serum SPF. He said: "SPF serums usually have less chance of leaving a white cast than traditional sunscreen formulations, because their formulations minimise the visible residue that most sunscreens are associated with.
"They're also lightweight and fast-absorbing, and often contain additional ingredients that benefit the skin, such as vitamins and antioxidants. Some also include ingredients that offer additional benefits, such as helping to address premature ageing, as well as brightening and hydrating the skin," as reported by Who What Wear.
Beauty brands such as Nivea, L'Oreal, The Ordinary and Hello Sunday to name a few have joined the hype and delivered sun protection packed with skin-loving benefits. These new products promise hydration and brightening as well as sun protection.
Sunscreen acts as a shield for your skin cells and protects your skin from damage, and a high factor gives you the best chance of protection. Dr Phillips added: "Serum SPF can be as effective as a traditional SPF formula, especially if you choose one with a high factor.
Help us improve our content by completing the survey below. We'd love to hear from you!
"Like traditional SPFs, you do need to ensure you are applying and reapplying enough product to get the full UV protective benefits. Serum SPF should be the last step in your skincare routine [they are under-makeup SPFs], and applied liberally to the face and neck."
We've handpicked a few of the most popular SPF serums out there...
Nivea Sun Face 2in1 Daily Primer Face Serum SPF50+
Nivea Sun Face 2in1 Daily Primer Face Serum SPF50+ promises immediate protection against UVA/UVB rays, providing noticeably smooth skin and preparing it for a flawless and prolonged make-up finish, as it also acts as a primer, making it the perfect base for makeup.
The Ordinary UV Filters SPF 45 Serum - £12.64, was 15.80
With a sheer, blendable finish, The Ordinary UV Filters SPF 45 Serum shields your skin from harmful UV exposure, while delivering a smooth, radiant glow. Infused with a blend of hydrators, the serum quenches your complexion to leave it feeling super soft.
Hello Sunday SPF 50 Hydrating and Brightening Vitamin C Serum - £18.40, was £23.00
Designed to simplify your daily skincare routine, the Hello Sunday SPF 50 Hydrating and Brightening Vitamin C Serum combines your daily serum, moisturiser and sunscreen, all in one. Enriched with antioxidants, brightening Vitamin C and hydrating Hyaluronic acid, it targets dullness, moisture loss and premature signs of aging, for plumper, nourished and more radiant skin, instantly and over time.
Ultra Violette Queen Screen SPF 50+ Luminising Skinscreen Serum- £38
Ultra Violette Queen Screen SPF 50+ Luminising Skinscreen Serum is an ultra-lightweight product that melts seamlessly into the skin to deliver a radiant glow and shield from damaging UV rays. Bursting with complexion-caring ingredients, it's packed with pink algae extract which increases firmness, smooths and reduces the appearance of dark spots alongside brightening vitamin C.
Garnier Ambre Solaire Super Uv Invisible Face Serum SPF 50+ - £6.99 was £14
Garnier Ambre Solaire Super Uv Invisible Face Serum SPF 50+ offers comfortable daily wear with very high SPF 50+ protection against UVB, UVA & long UVA. Developed for sensitive skin, it helps fight against external aggressions and skin pollution.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Daily Mirror

8 hours ago

• Daily Mirror

Major supermarket's sun cream spray fails safety tests as best sunscreens ranked

Which? tested 15 different sun creams to rate the best sunscreen to protect your skin this summer. Two products, one from Morrisons and the other from Ultrasun, failed their test A Morrisons sun spray has failed key safety tests, Which? has said, as it ranked the best-buy products for this summer. In their recent investigation, the consumer organisation tested 15 different sun creams, including big brands, own-label products and supermarket options. The sunscreen tested ranged from SPF30 to SPF50+ - and two of the items didn't pass the test. After testing it twice, Which? said Morrisons SPF30 sun spray - which costs £3.75 for 200ml - didn't meet the claimed SPF level - which is what protects your skin from UVB rays. The publication said it informed Morrisons of the test results, and the supermarket giant said it is looking at the data and working with its supplier to carry out further independent testing. ‌ ‌ According to the test carried out by Which? Ultrasun Family SPF30 lotion - priced at £28 for 150ml - also failed to match the minimum required UVA level for an SPF30 product in either the initial or repeat test. The organisation said that while the sunscreen passed its SPF (sun protection factor) test, it failed on the UVA front, meaning they would not recommend buying it. A spokesperson from Ultrasun told Which? it was fully confident in its testing protocols and that its detailed testing processes continued to not only meet, but surpass industry standards. It stated that its chosen testing protocol is one of the strictest available. Which? said that as part of its test, which uses industry-recognised methods, if a product failed on a first test, it was repeated. If it passed the second time, a third test was be done. But if a product failed the SPF or UVA twice overall, it became a "don't buy" as part of its recommendations. Among the sunscreen that passed was budget supermarket Aldi 's Lacura Sensitive Sun Lotion SPF50+, which costs just £2.99 for 200ml. Which? said they found this product protected the skin from both UVA and UVB rays, as claimed. The product - priced at £1.50 per 100ml - also earned a Which? Great Value badge. Similarly, Lidl's Cien Sun Spray 30 SPF High, costing £3.79 for 200ml, was given the same rating. Other SPF30 products that passed the test included Boots Soltan Protect & Moistorise, both as lotion and as spray - which are both priced at £5.50 per 200ml. Nivea Sun Protect & Moisture Lotion SPF30, Sainsbury's SPF30 Moisturising Lotion and Superdrug Solait Sun Spray SPF30 also passed the test. Among the SPF50 sunscreen approved by Which? are Aldi SPF50+ Sensitive Lotion, which costs £2.99 per 200ml, and was also given a Great Value badge. Boots Soltan Protect & Moisturise Lotion SPF50+, Garnier Ambre Solaire Sensitive Advanced Sun Spray SPF50+, Nivea Sun Protect & Moisture Spray SPF50+ and Sainsbury's SPF50+ Moisturising Spray Lotion were all successful too. Which? also tested two sunscreen for children - Boots Soltan Kids Protect & Moisturise Lotion SPF50+ and Childs Farm SPF50+ Sun Cream Fragrance-Free - and they both passed the test.

The Independent

12 hours ago

• The Independent

Painful symptom of latest Covid variant identified

The NB.1.8.1, or "Nimbus," Covid variant is now nearly the most prevalent omicron lineage tracked by the CDC. A notable symptom associated with Nimbus is an incredibly painful "razor blade throat," though other symptoms are typical of Covid infection. Experts state that despite its rapid spread, the Nimbus variant does not appear to be more severe than previous strains. The variant's quick transmissibility is attributed to genetic mutations that allow it to bind easily to human cells. The World Health Organization has designated Nimbus as a "variant under monitoring" and considers the global public health risk to be low, with current vaccines expected to remain effective.

The Independent

17 hours ago

• The Independent

US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need

US medicines regulator the Food and Drug Administration (FDA) has approved a groundbreaking HIV prevention jab hailed as having the potential to quell the Aids pandemic. But the moment has been overshadowed by the spectre of aid cuts, placing in doubt whether this breakthrough injection – lenacapavir – will get to the people who need it most. Lenacapavir given in a twice-yearly injection stops HIV from replicating, protecting close to 100 per cent of people from developing the virus if they are exposed to it. This approval is one of the last crucial steps to getting the drug, branded Yeztugo, out to patients. Although the FDA's approval only applies to US patients, the World Health Organization (WHO) said it paved the way for its own recommendation of the drug and for approval in other countries. Director of WHO's Global HIV, Hepatitis and STI Programmes, Dr Meg Doherty described it as a 'regulatory milestone' adding: 'We are working with partners and national authorities to ensure lenacapavir reaches people who need it most – quickly, safely and equitably.' Researchers have raised concerns that, amid aid cuts, the jab will be too expensive to be taken up by lower-income countries. Gilead – the drugs company producing lencapavir – did not make public the cost of each dose to global funders but it announced a US price of $28,218 per year for each patient. 'If this game-changing medicine remains unaffordable, it will change nothing,' said Winnie Byanyima, executive director of the United Nations' Aids agency, UNAIDS. She called the approval of lenacapavir a 'breakthrough moment' adding the jab, 'could be the tool we need to bring new infections under control – but only if it is priced affordably and made available to everyone who could benefit. ' UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of roll out. It is beyond comprehension how Gilead can justify a price of $28,218.' Dr Andrew Hill, a pharmacology research fellow at the University of Liverpool, worked on the research which found lenacapavir could be provided for as little as $25, including a 30 per cent profit margin. 'Scientifically, it's a great moment that we have a drug which has been judged to be safe and efficacious by a leading regulatory authority in the world,'' he said. 'Public health-wise and in terms of the epidemic, it's tragic because the drug is so expensive that it's not going to get used'. It is also unlikely to be affordable in the UK, he said, despite government promises to end new cases of HIV in England by 2030. A Gilead spokesperson said, 'Yeztugo is priced in line with existing branded PrEP [pre-exposure prophylaxis] options. We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage in the US. 'We're taking unprecedented actions with urgency to plan for access to lenacapavir for PrEP globally—particularly in low- and lower-middle-income countries where the need is greatest.' Gilead signed agreements with six pharmaceutical companies in India, Pakistan, Egypt, and the US to allow them to make generic versions of the drug in order to increase supply and drive down the cost of the jab. This will take some time. Gilead also agreed to sell enough doses of the jab to protect at least two million people over three years in lower-income countries. These would be paid for by global funders led by the US President's Emergency Plan for Aids Relief (Pepfar) and the Global Fund to Fight Aids, Tuberculosis and Malaria. However, The Independent reported earlier in the month that these doses are now at risk because of US funding cuts. A significant chunk of the money to fund the doses of lenacapavir was set to come from the US-led global Aids response programme, Pepfar, as well as the Global Fund whose biggest donor was the US. This funding is now uncertain. Figures previously reported by The Independent suggest President Trump's slashing of foreign aid has derailed the projected end of the Aids pandemic and could lead to four million extra deaths by 2030. 'It does feel like this thing that could help us end the epidemic sooner is suddenly receding in the chaos,' said Prof Linda-Gail Bekker, whose trial demonstrated lenacapavir's effectiveness. The aid-funded doses are thought to cost much less than the US list price of almost $30k but still roughly five times more expensive than Dr Hill believes is necessary. And they are in an initial pilot phase, he said: 'We need to get into a different level where we're giving lenacapavir to tens of millions of people'. This is even more important as aid cuts are slashing the HIV prevention budgets of governments across Africa, he said. 'We're in this crazy position where we have a brand new highly effective vaccine-like drug and actually we will probably see the epidemic get worse over the next four years.'